Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Claudin6-CAR-T
- Development stage
- Preclinical
- Lead developer
- BioNTech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Claudin6-CAR-T is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy being developed by Innovative Therapies for the treatment of ovarian cancer. This therapeutic approach involves the genetic modification of a patient's T cells to express a CAR specific to Claudin 6 (CLDN6), a tight junction protein that is highly expressed in several solid tumors, including ovarian and germ cell tumors, but is virtually absent in healthy adult tissues. By leveraging the specificity of the anti-CLDN6 CAR, the therapy aims to direct the cytotoxic activity of T cells precisely against CLDN6-positive malignant cells, thereby minimizing off-target effects and providing a potent immunotherapy option for patients with advanced ovarian cancer.
- Other names
- Claudin 6-targeted CAR-T cellsClaudin6-targeted CAR-T cellsClaudin-6-targeted CAR-T cellsCLDN6-CAR-T cell therapyCLDN-6-CAR-T cell therapyCLDN 6-CAR-T cell therapy
02
Targets
CLDN6 (Claudin-6)
Beyond the preview
Go deeper on Claudin6-CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin6-CAR-T.